Utriainen Meri, Metsähonkala Liisa, Salmi Toivo T, Utriainen Tapio, Kalimo Hannu, Pihko Helena, Mäkipernaa Anne, Harila-Saari Arja, Jyrkkiö Sirkku, Laine Jukka, Någren Kjell, Minn Heikki
Turku PET Centre, University of Turku, Finland.
Cancer. 2002 Sep 15;95(6):1376-86. doi: 10.1002/cncr.10798.
Positron emission tomography (PET) scans of primary brain tumors were performed in pediatric patients to examine whether metabolic characteristics could be used as an index of clinical aggressiveness.
Twenty-seven pediatric patients with untreated primary central nervous system neoplasms were studied with PET scans using 2-[(18)F] fluoro-2-deoxy-D-glucose (FDG) and/or L-[methyl-(11)C] methionine (MET). Metabolic characteristics as assessed with FDG and MET standardized uptake values (SUV) and SUV-to-normal brain ratios were compared with histopathology and selected histochemical features such as proliferation activity (Ki-67(MIB-1)) and apoptotic, vascular, and cell density indices. The median followup time was 43 months.
The accumulation of both FDG and MET was significantly higher in high-grade than in low-grade tumors, but a considerable overlap was found. The accumulation of both tracers was associated positively with age. High-grade tumors showed higher proliferative activity and vascularity than the low-grade tumors. In univariate analysis, FDG-PET, MET-PET, and apoptotic index were independent predictors of event-free survival.
We found that both FDG and MET uptake in pediatric brain tumors are associated with malignancy grade. However, no clear limits of SUVs and SUV-to-normal brain ratios can be set between low-grade and high-grade tumors, which makes the assessment of malignancy grade using metabolic imaging with PET scan difficult in individual cases. Although FDG-PET and MET-PET do not compensate for histopathologic evaluation, they may give valuable additional information especially if invasive procedures to obtain histopathologic samples are not feasible.
对小儿原发性脑肿瘤患者进行正电子发射断层扫描(PET),以检查代谢特征是否可作为临床侵袭性的指标。
对27例未经治疗的原发性中枢神经系统肿瘤患儿进行PET扫描,使用2-[(18)F]氟-2-脱氧-D-葡萄糖(FDG)和/或L-[甲基-(11)C]蛋氨酸(MET)。将通过FDG和MET标准化摄取值(SUV)以及SUV与正常脑比值评估的代谢特征与组织病理学以及选定的组织化学特征(如增殖活性(Ki-67(MIB-1))、凋亡、血管和细胞密度指数)进行比较。中位随访时间为43个月。
高级别肿瘤中FDG和MET的积聚均显著高于低级别肿瘤,但发现有相当程度的重叠。两种示踪剂的积聚均与年龄呈正相关。高级别肿瘤比低级别肿瘤显示出更高的增殖活性和血管生成。在单变量分析中,FDG-PET、MET-PET和凋亡指数是无事件生存期的独立预测因素。
我们发现小儿脑肿瘤中FDG和MET摄取均与恶性程度相关。然而,在低级别和高级别肿瘤之间无法设定SUV以及SUV与正常脑比值的明确界限,这使得在个别病例中使用PET扫描代谢成像评估恶性程度变得困难。尽管FDG-PET和MET-PET不能替代组织病理学评估,但它们可能提供有价值的额外信息,特别是在获取组织病理学样本的侵入性操作不可行时。